SNY - Blueprint Receives FDA Approval And Other News: The Good Bad And Ugly Of Biopharma
FDA approves Blueprint’s GAVRETO for lung cancer
Blueprint Medicines Corporation (BPMC) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is collaborating with Roche (RHHBY), and the drug will be commercialized in the United States by the company and Genentech, a member of the Roche Group.
Blueprint supported its application to the FDA with the data from the Phase 1/2 ARROW clinical trial. The results demonstrated that the drug candidate was effective in patients with